camptothecin has been researched along with evodiamine in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, ZS; Li, D; Qiu, Y; Wu, L; Xu, J; Xu, S; Yang, DH; Yao, H; Zhou, M | 1 |
| Goon, S; Kundu, B; Mondal, MA; Sarkar, D; Talukdar, A | 1 |
| Chang, YL; Guh, JH; Huang, DY; Liao, CH; Liu, YN; Pan, SL; Peng, CY; Teng, CM | 1 |
| Chen, CE; Chen, CS; Hwang, J; Lai, ZY; Lin, CM; Lin, LW; Tsai, HP; Wu, JY | 1 |
| Bligh, SW; Hartley, JA; Hartley, JM; Pan, X; Wang, Z; White, KN | 1 |
| Guan, W; Liu, B; Qian, X; Shen, J; Wang, H; Wei, J; Yu, L; Yue, G; Zou, Z | 1 |
| Jin, DY; Lou, WH; Rong, YF; Wu, W; Xu, XF; Zhang, L | 1 |
1 review(s) available for camptothecin and evodiamine
| Article | Year |
|---|---|
Topoisomerase I inhibitors: Challenges, progress and the road ahead.
Topics: Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; Irinotecan; Poisons; Topoisomerase I Inhibitors | 2022 |
6 other study(ies) available for camptothecin and evodiamine
| Article | Year |
|---|---|
Discovery of Novel Polycyclic Heterocyclic Derivatives from Evodiamine for the Potential Treatment of Triple-Negative Breast Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Female; Heterocyclic Compounds; Humans; Polycyclic Compounds; Quinazolines; Triple Negative Breast Neoplasms | 2021 |
Evodiamine represses hypoxia-induced inflammatory proteins expression and hypoxia-inducible factor 1alpha accumulation in RAW264.7.
Topics: Animals; Anti-Inflammatory Agents; Blotting, Western; Camptothecin; Cell Hypoxia; Cell Line; Cyclooxygenase 2; Dinoprostone; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gene Expression Regulation; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; NF-kappa B; Nitric Oxide Synthase Type II; Phosphorylation; Plant Extracts; Proto-Oncogene Proteins c-akt; Pyrrolidines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Ribosomal Protein S6 Kinases, 70-kDa; Thiocarbamates | 2009 |
Immobilizing topoisomerase I on a surface plasmon resonance biosensor chip to screen for inhibitors.
Topics: Camptothecin; Comet Assay; DNA; DNA Damage; DNA Topoisomerases, Type I; Drug Evaluation, Preclinical; Enzyme Inhibitors; Enzymes, Immobilized; Humans; In Vitro Techniques; Kinetics; Macromolecular Substances; Models, Molecular; Plant Extracts; Quinazolines; Recombinant Proteins; Surface Plasmon Resonance; Topoisomerase I Inhibitors | 2010 |
Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Proliferation; DNA Damage; DNA Topoisomerases; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Drugs, Chinese Herbal; Evodia; Fruit; Humans; Inhibitory Concentration 50; Leukemia; Phytotherapy; Quinazolines; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topoisomerase Inhibitors | 2012 |
Synergistic anticancer effects of polyphyllin I and evodiamine on freshly-removed human gastric tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Confidence Intervals; Diosgenin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Platinum; Quinazolines; RNA, Messenger; Stomach Neoplasms | 2013 |
SN38 increases IL-8 expression through the MAPK pathways in HCT8 cells.
Topics: Berberine; Camptothecin; Cell Line, Tumor; Cell Survival; Fluorouracil; Humans; Interleukin-8; Irinotecan; Janus Kinase 2; MAP Kinase Signaling System; Phosphorylation; Quinazolines; Up-Regulation | 2017 |